Receptor tyrosine kinase inhibitors in thyroid cancer.

Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.

[1]  L. Bresler*,et al.  Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[3]  B. Ponder,et al.  Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. , 1996, Cancer research.

[4]  M. Rothmund,et al.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines , 2007, Endocrine.

[5]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[6]  J. Franklyn,et al.  Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[7]  Antonio Duarte,et al.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation , 2008, Nature.

[8]  K. Franssila,et al.  MET Receptor Tyrosine Kinase Sequence Alterations in Differentiated Thyroid Carcinoma , 2005, The American journal of surgical pathology.

[9]  R. Kurzrock,et al.  Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib , 2008, Molecular Cancer Therapeutics.

[10]  Thomas J Lynch,et al.  A phase II study of gefitinib in patients with advanced thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[11]  M. Ringel,et al.  Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. , 2008, Endocrinology and metabolism clinics of North America.

[12]  L. Akslen,et al.  Expression of c-erbB-2 protein in papillary thyroid carcinomas. , 1992, British Journal of Cancer.

[13]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[14]  C. Plass,et al.  Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants , 2001, International journal of cancer.

[15]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[16]  J. Luk,et al.  Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node Metastases , 2005, Clinical Cancer Research.

[17]  C. Heldin,et al.  Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[19]  N. Mitsiades,et al.  Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. , 2006, The Journal of clinical endocrinology and metabolism.

[20]  E. Baudin,et al.  New therapeutic approaches to treat medullary thyroid carcinoma , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[21]  V. Detours,et al.  Gene expression and the biological phenotype of papillary thyroid carcinomas , 2007, Oncogene.

[22]  A. Costantino,et al.  Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. , 2004, Endocrinology.

[23]  E. Surmacz.  Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor , 2003, Oncogene.

[24]  L. Bastholt,et al.  Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.

[25]  J. Dumont,et al.  Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. , 2007, Experimental cell research.

[26]  L. Mariani,et al.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.

[27]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[28]  R. Schmid,et al.  Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. , 2001, Cancer research.

[29]  A. El‐Naggar,et al.  Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer , 2004, Clinical Cancer Research.

[30]  Wei Liu,et al.  Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. , 2005, Endocrinology.

[31]  G. Viglietto,et al.  Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. , 1995, Oncogene.

[32]  Q. Duh,et al.  Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. , 1997, The Journal of clinical endocrinology and metabolism.

[33]  Li Yan-fu.  c-met Expression in Tall Cell Variant Papillary Carcinoma of The Thyroid , 2008 .

[34]  H. Namba,et al.  BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. , 2006, Endocrinology.

[35]  Ling Wang,et al.  AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. , 2006, Cancer research.

[36]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Santoro,et al.  Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[38]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[39]  M. Pierotti,et al.  Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.

[40]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Mol,et al.  Switching on kinases: oncogenic activation of BRAF and the PDGFR family , 2004, Nature Reviews Cancer.

[42]  K. Matsumoto,et al.  Mitogenic, dedifferentiating, and scattering effects of hepatocyte growth factor on dog thyroid cells. , 1994, Endocrinology.

[43]  D. Pfister,et al.  Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial , 2007 .

[44]  S. Delorme,et al.  Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. , 2007, European journal of endocrinology.

[45]  M. Ratain,et al.  A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) , 2008 .

[46]  H. Yao,et al.  Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells , 2007, The Journal of pathology.

[47]  Y. Nobuhara,et al.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines , 2005, British Journal of Cancer.

[48]  M. Fleisher,et al.  Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. , 2002, The Journal of clinical endocrinology and metabolism.

[49]  E. Voest,et al.  A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[50]  J. Dumont,et al.  Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. , 2000, The Biochemical journal.

[51]  J. Osinga,et al.  Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. , 2006, Surgery.

[52]  Wei Liu,et al.  Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. , 2007, Cancer research.

[53]  Steven J. M. Jones,et al.  Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  L. Akslen,et al.  Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. , 1996, Cancer research.

[55]  D. Fabbro,et al.  RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. , 2008, Cancer research.

[56]  F. Kelleher,et al.  Response to sunitinib in medullary thyroid cancer. , 2008, Annals of internal medicine.

[57]  M. Papotti,et al.  Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid , 2000, Endocrine pathology.

[58]  Svend Kjær,et al.  Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.

[59]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[60]  B. Ponder,et al.  Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. , 2004, Journal of the National Cancer Institute.

[61]  C. Bucana,et al.  Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. , 2005, Cancer research.

[62]  Krzysztof Fujarewicz,et al.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping , 2007, Endocrine-related cancer.

[63]  Q. Duh,et al.  Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[64]  K. Ain,et al.  Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. , 2004, The Journal of clinical endocrinology and metabolism.

[65]  M. Mandal,et al.  Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 , 2005, Molecular Cancer Therapeutics.

[66]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[67]  A. Leonardi,et al.  Oncogenic and Anti-apoptotic Activity of NF-κB in Human Thyroid Carcinomas* , 2004, Journal of Biological Chemistry.

[68]  E. Vokes,et al.  Phase 2 study of sunitinib in refractory thyroid cancer , 2008 .

[69]  H. Lodish.  Molecular Cell Biology , 1986 .

[70]  J. Sebolt-Leopold,et al.  Mechanisms of drug inhibition of signalling molecules , 2006, Nature.

[71]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[72]  P. Mires.  Lines , 2006 .

[73]  K. J. Kim,et al.  Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo , 2000, Surgery.

[74]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.

[75]  A. El‐Naggar,et al.  Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. , 2008, Human pathology.

[76]  A. Leonardi,et al.  Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. , 2004, The Journal of biological chemistry.

[77]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[78]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[79]  P. Couvreur,et al.  siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma , 2007, Nucleic acids research.

[80]  C. Bucana,et al.  Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma , 2006, Clinical Cancer Research.

[81]  Seungwon Kim,et al.  The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model , 2007, Clinical Cancer Research.

[82]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[83]  Ta‐Jen Wu,et al.  Clinical Relevance of Vascular Endothelial Growth Factor for Thyroid Neoplasms , 2001, World Journal of Surgery.

[84]  Elke S. Bergmann-Leitner,et al.  Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner] , 2005 .

[85]  David E. Misek,et al.  Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis , 2005, Oncogene.

[86]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[87]  J. Franklyn,et al.  Expression of fibroblast growth factors in thyroid cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[88]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[89]  D. McMillin,et al.  Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. , 2006, The Journal of clinical endocrinology and metabolism.

[90]  Steven J. M. Jones,et al.  Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis , 2008, Annals of Surgical Oncology.

[91]  A. Gabizon,et al.  The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. , 2006, Endocrine-related cancer.

[92]  S. Dawson,et al.  Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. , 2008, Anti-Cancer Drugs.

[93]  Gary L Clayman,et al.  Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma , 2008, Head & neck.

[94]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[95]  P. Hou,et al.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. , 2008, The Journal of clinical endocrinology and metabolism.

[96]  Jung Hun Song,et al.  An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. , 2006, The Journal of clinical endocrinology and metabolism.

[97]  M. Pierotti,et al.  Oncogenic rearrangements of the NTRK1/NGF receptor. , 2006, Cancer letters.

[98]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[99]  D. Grimm,et al.  Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. , 2004, Endocrinology.

[100]  S. Baylin,et al.  Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. Asa,et al.  Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[102]  M. Nikiforova,et al.  Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. , 2006, The Journal of clinical endocrinology and metabolism.

[103]  J. Wass,et al.  Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. , 2004, Endocrine-related cancer.

[104]  C. Strock,et al.  Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.